Home/Filings/4/0001209191-20-041329
4//SEC Filing

BRYCE RICHARD PAUL 4

Accession 0001209191-20-041329

CIK 0001401667other

Filed

Jul 5, 8:00 PM ET

Accepted

Jul 6, 8:02 PM ET

Size

5.5 KB

Accession

0001209191-20-041329

Insider Transaction Report

Form 4
Period: 2020-07-02
BRYCE RICHARD PAUL
SR VP, CLINICAL RESEARCH & DEV
Transactions
  • Sale

    COMMON STOCK

    2020-07-02$10.67/sh660$7,04077,083 total
Footnotes (2)
  • [F1]The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5701 to $10.6676, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Issuer

PUMA BIOTECHNOLOGY, INC.

CIK 0001401667

Entity typeother

Related Parties

1
  • filerCIK 0001553037

Filing Metadata

Form type
4
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 8:02 PM ET
Size
5.5 KB